In an attempt to produce better cytotoxic analogues, chemotherapeutic antineoplastic radicals including an alkylating nitrogen mustard derivative of D-phenylalanine (D-melphalan), reactive cyclopropane, anthraquinone derivatives [2-(hydroxymethyl)anthraquinone and the anticancer antibiotic doxorubicin], and an antimetabolite (methotrexate) were coupled to suitably modified agonists and antagonists of luteinizing hormone-releasing hormone (LH-RH). Analogues with D-lysine' and D-ornithine6 or N8-(2,3-diaminopropionyl)-D-lysine and N8-(2,3-diaminopropionyl)-D-ornithine were used as carriers for one or two cytotoxic moieties. The enhanced biological activities produced by the incorporation of D amino acids into position 6 of the agonistic analogues were further increased by the attachment of hydrophobic cytotoxic groups, resulting in compounds with 10-50 times higher activity than LH-RH. Most of the monosubstituted agonistic analogues showed high affinities for the membrane receptors of human breast cancer cells, while the receptor binding afnities of peptides containing two cytotoxic side chains were lower. Chemotherapy has been, for many decades, one of the main approaches for the treatment of malignant neoplasms. Despite the development of modem, more specific cytotoxic drugs, their nonselective action on cells other than cancerous ones remains a major problem. A recent modality for the treatment of hormone-sensitive tumors is based on the use of agonists and antagonists of luteinizing hormone-releasing hormone (LH-RH) (1). Some LH-RH agonists substituted in position 6, 10, or both are much more active than LH-RH and also possess prolonged activity (1-3). Changes in positions 1, 2, 3, and 6 and occasionally in positions 5 and 10 of the LH-RH molecule lead to the formation of powerful antagonists (1-4), which inhibit the release of LH and folliclestimulating hormone from the pituitary, create a state of sex-steroid deprivation, and thus have potential therapeutic applications in the treatment of some hormone-dependent cancers such as those of prostate and breast (1, 5).
Chemotherapy has been, for many decades, one of the main approaches for the treatment of malignant neoplasms. Despite the development of modem, more specific cytotoxic drugs, their nonselective action on cells other than cancerous ones remains a major problem. A recent modality for the treatment of hormone-sensitive tumors is based on the use of agonists and antagonists of luteinizing hormone-releasing hormone (LH-RH) (1) . Some LH-RH agonists substituted in position 6, 10, or both are much more active than LH-RH and also possess prolonged activity (1) (2) (3) . Changes in positions 1, 2, 3, and 6 and occasionally in positions 5 and 10 of the LH-RH molecule lead to the formation of powerful antagonists (1-4), which inhibit the release of LH and folliclestimulating hormone from the pituitary, create a state of sex-steroid deprivation, and thus have potential therapeutic applications in the treatment of some hormone-dependent cancers such as those of prostate and breast (1, 5 HPLC. All synthetic peptides were purified as described (4, 6, 7) . Amino acid analyses were also performed as reported (4, 6, 7) .
LH-Releasing and LH-RH-Inhibiting Activities. Activities were evaluated in vitro by using a superfused rat pituitary cell system (8, 9) . In vivo antiovulatory activity of peptides was determined in 4-day-cycling rats as described (10) .
Receptor Binding. The affinity of peptides to human breast cancer cell membranes was determined by using '25I-labeled
Cytotoxicity Test. The ability of peptides to inhibit incorporation of [3H]thymidine into DNA of monolayer cultures of the human breast and prostate cancer cell lines was assayed as described (12, 13) . RESULTS 
Preparation of LH-RH Analogues with Cytotoxic Moieties.
Precursor peptides of cytotoxic analogues were synthesized by incorporation of D-Lys or D-Orn into position 6 of the native LH-RH sequence (AG-1 and AG-2) and by incorporation of D-Lys into three antagonistic analogues (ANT-1, ANT-2, and ANT-3) (AG, agonist; ANT, antagonist). To obtain precursors for incorporation of two cytotoxic groups, these peptides were acylated with 2,3-diaminopropionic acid, resulting in D-Lys(A2pr)-and D-Orn(A2pr)-containing precursors (AG-3, AG-4, ANT-4, ANT-5, and ANT-6). Accordingly, the general formulae are as follows:
AG-1, AG-2 Glp-His-Trp-Ser-Tyr-R6-Leu-Arg-Pro-Gly-NH2; AG-3, AG-4 Glp-His-Trp-Ser-Tyr-R6(A2pr)-Leu-Arg-ProGly-NH2;
where R3 is D-Trp or D-Pal(3) and R6 is D-Lys or D-Orn. The two isomers of MTX conjugates, formed by the indiscriminate activation of the a and 'y carboxyl groups of the glutamic acid moiety in MTX, were separated only in the case of AG-1 (VIII), although the two structural isomers formed with other precursors also have different retention times (XV, XXII, and XXIX).
Agonistic and Antagonistic Properties. LH-releasing activity of agonistic derivatives (I-XV) and their precursor peptides in a dispersed rat pituitary superfusion system is shown in Table 1 . Cytotoxic analogues showed 10-56 times higher potency than LH-RH itself and were 2-8 times more potent in releasing LH than their precursor peptides. LH-RH inhibiting potencies of the antagonistic conjugates (XVI-XXX) and their parent peptides are presented in Table 2 . Antago- (16, 21) . A combination of hormonal manipulation with targeted chemotherapy would enhance the efficacy of the treatment. This work and previous studies (5-7) show that LH-RH analogues might serve as carriers for chemotherapeutic agents. The conjugates would bind to receptors on cell membranes of tumors. This binding could be followed by internalization and a chain of events that might result in interference with the replication of neoplastic cells or even their destruction by the derivative of the cytotoxic analogue. The release of the cytotoxic moieties or their biologically active derivatives from the carrier hormone or the splitting of the bond between the drug and the peptide may not be an Proc. Natl. Acad Sci. USA 89 (1992) essential requirement, since drugs linked to peptides or proteins by nonhydrolyzable covalent bonds can produce active drug-carrier conjugates as described by Varga (22) .
In the present study, anticancer drugs or structurally related cytotoxic radicals were coupled to LH-RH agonists (AG-1 and -2) and antagonists (ANT-1 and -2). By preparation of analogues containing two amino groups (AG-3 and -4; ANT-4, -5, and -6), we were able to double the cytotoxic moiety/peptide ratio.
Hydrophobic D amino acid residues at position 6 ofLH-RH greatly increase the LH-releasing activity of the parent hormones (3, 6) . (Table 2) . One analog, T-144 (XXX), having Pal(3)3 and Tyr5 in the peptide chain showed very high cytotoxic activity in vitro.
Alkylating agents used in the treatment of cancer have a basically nonselective mechanism of action (23) . They act by exerting cytotoxic effects through transfer of their alkyl groups to various cell constituents. Alkylation ofDNA within the nucleus probably represents the major interaction that leads to cell death. Nitrogen mustards (chlorambucil, cyclophosphamide, Mel) are among the oldest anticancer drugs in clinical use. Initially the incorporation of alkylating chlorambucil 4-[bis(2-chloroethyl)amino]benzenebutanoic acid into LH-RH agonists and antagonists in an attempt to make contraceptive analogues led to compounds with low or no activity (24) . Our work shows that LH-RH analogues containing D-Mel have high agonistic and antagonistic activity and bind to the rat pituitary, human breast, and human prostate cancer cell membranes with high affinity (6) . We could demonstrate significant cytotoxic activity of these compounds as based on Cyclopropane with its three-membered ring is another alkylating agent. Receptor binding of analogues with CPC (III, IV, XI, XIX, XXVI) to cancer cell membrane was decreased or completely absent (XII, XVIII, XXV). This indicates that no alkylation of receptors has occurred. At the same time, XVIII exhibited a strong and prolonged antagonistic effect in vitro.
Many drugs used in cancer chemotherapy contain a quinone group in their structure. Anthracycline antitumor antibiotics such as Dox bind to DNA through intercalation between specific bases and block the synthesis of new RNA or DNA (or both), cause DNA strand scission, and interfere with cell replication (25) . When Dox was coupled to peptide carrier melanotropin, the conjugate proved to be more toxic to murine melanoma cells than the free drug (22) . Coupling Dox to AG-1 through a glutaric acid bridge resulted in a conjugate (VII) with low receptor binding and moderately elevated agonistic activity.
2-(Hydroxymethyl)anthraquinone derivatives have cytotoxic activity on hypoxic neoplastic cells (26) . Compounds V, VI, XIII, and XIV contain 2-(hydroxymethyl)anthraquinone substituent bridged to agonistic LH-RH analogues. Their high agonistic activity is probably due to the hydrophobic anthraquinone structure, although their receptor binding on cancer cell membranes is low. In contrast, antagonistic analogues (XX, XXVII, and XXX) bind to receptors with 2-10 times higher affinity than their parent peptides. The Medical Sciences: Jandky et al.
extremely high and long-lasting antagonistic activity of XX (T-117) might be explained by its slow dissociation from the receptor binding sites.
Several antimetabolites are of potential chemotherapeutic interest because of their importance in cellular folate metabolism (27) . MTX is a folic acid antagonist that inhibits the function of dihydrofolate reductase and in this way interrupts the synthesis of thymidilate, purine nucleotides, and the amino acids serine and methionine, thereby interfering with the formation of DNA, RNA, and proteins (27) . MTX containing LH-RH agonist (VIII) had good binding affinity and cytotoxic activity.
Some of these LH-RH analogues were evaluated in vitro for cytotoxicity in cell cultures of various mammary and prostate cancer cell lines. Compounds I-XXX inhibited [3H]thymidine incorporation, but the inhibition rates differed from cell line to cell line. Several factors influence the cytotoxicity of these compounds, including receptor binding, which was discussed above, but generally the antagonistic analogues carrying cytotoxic radicals bind with lower affinities than the agonistic ones. Pure agonistic analogues are internalized in pituitary cells much faster (1-3 min) than antagonistic peptides (20) . In spite of this, there were no significant differences between cytotoxicity of I-XV and XVI-XXX. In addition to exerting cytotoxic activity in vitro, some analogues reported here inhibited the growth of Dunning R3327H prostate cancer in rats and breast cancers in mice. Cytotoxic LH-RH analogues (VIII), AJ-04 (agonist [D-Lys6]LH-RH linked to MTX, (V) T-98 {[D-Lys6]LH-RH coupled to HMAQG and (XXVIII) T-121 (antagonist containing 2 residues of HMAQG) produced a significant inhibition of tumor growth in female BDF1 mice bearing MTX (3.2)/Ovex}, estrogen-independent mammary tumors. These results indicate that LH-RH analogues containing cytotoxic radicals retain their hormonal activity after administration in vivo and can apparently be bound to tumors that have receptors for LH-RH. Our studies suggest the merit offurther development of LH-RH analogues containing cytotoxic radicals.
